title: Oral vinorelbine in the treatment of non-small-cell lung cancer.
abstract: BACKGROUND
  Originally formulated as an intravenous (i.v.) agent, vinorelbine is also currently available as an oral chemotherapeutic agent. Oral vinorelbine has demonstrated significant activity in different settings for NSCLC, including adjuvant treatment for resected disease, concurrent chemoradiation for locally advanced NSCLC and palliative chemotherapy for recurrent/metastatic NSCLC, as part of combination schedules or as a single-agent treatment.
  
  
  METHODS
  The authors explored the available data describing the use of oral vinorelbine in NSCLC. PubMed articles and abstracts presented at international conferences were analysed, and relevant trials were reported and discussed. Specific settings, including the treatment of elderly and unfit patients and metronomic schedules including oral vinorelbine, were evaluated. Available pharmacoeconomic data were also assessed.
  
  
  CONCLUSIONS
  Oral vinorelbine is an appealing agent, particularly as part of combination regimens containing platinum derivatives, although it can have a role as a single-agent treatment as well. Its safety profile is generally favourable and its route of administration is generally preferred by patients receiving chemotherapy. Compared to i.v. vinorelbine and other antineoplastic agents, oral vinorelbine has been reported to be advantageous in terms of cost savings.
authors: UOS Tumori Polmonari, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro , Genova , Italy fg1965@libero.it.
authors: Giulia
authors: G
authors: Barletta
authors: Carlo
authors: C
authors: Genova
authors: Erika
authors: E
authors: Rijavec
authors: Giovanni
authors: G
authors: Burrafato
authors: Federica
authors: F
authors: Biello
authors: Claudio
authors: C
authors: Sini
authors: Maria Giovanna
authors: MG
authors: Dal Bello
authors: Simona
authors: S
authors: Coco
authors: Anna
authors: A
authors: Truini
authors: Irene
authors: I
authors: Vanni
authors: Angela
authors: A
authors: Alama
authors: Sabrina
authors: S
authors: Beltramini
authors: Maria Attilia
authors: MA
authors: Grassi
authors: Francesco
authors: F
authors: Boccardo
authors: Francesco
authors: F
authors: Grossi
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine
keywords: chemotherapy; non-small-cell lung cancer; oral vinorelbine; vinca alkaloid